Mank, Arenda
van Maurik, Ingrid S.
Rijnhart, Judith J. M.
bakker, Els D.
Bouteloup, Vincent
Le Scouarnec, Lisa
Teunissen, Charlotte E.
Barkhof, Frederik
Scheltens, Philip
Berkhof, Johannes
van der Flier, Wiesje M.
Article History
Received: 12 January 2022
Accepted: 27 July 2022
First Online: 5 August 2022
Declarations
:
: The study was approved by the local Medical Ethical Committee. All patients provided written informed consent for their clinical data to be used for research purposes.
: Not applicable.
: Arenda Mank, Ingrid S. van Maurik, Els D. Bakker, Vincent Bouteloup, Lisa Le Scouarnec, and Johannes Berkhof report no financial disclosures or conflicts of interest.Judith J.M. Rijnhart received a grant from the Amsterdam Public Health Research Institute, which was paid to the Amsterdam UMC.Charlotte E. Teunissen was supported by funding from the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. C.E. Teunissen has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research, or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, and Vivoryon. C.E. Teunissen serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, and Neurology: Neuroimmunology & Neuroinflammation and is editor of a Neuromethods book Springer.Frederik Barkhof is a steering committee or iDMC member for Biogen, Merck, Roche, EISAI, and Prothena. FB is a consultant for Roche, Biogen, Merck, IXICO, Jansen, and Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD. FB is supported by the NIHR biomedical research centre at UCLH.Philip Scheltens has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell, and Green Valley. Within his university affiliation, he is global PI of the phase 1b study of AC Immune, phase 2b study with FUJI-film/Toyama, phase 2 study of UCB, and phase 1 study with ImmunoBrain Checkpoint. He is chair of the EU steering committee of the phase 2b program of Vivoryon, the phase 2b study of Novartis Cardiology, and co-chair of the phase 3 study with NOVO-Nordisk. He is also an employee of EQT Life Sciences (formerly LSP).Wiesje M. van der Flier: Research programs of W.M. van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF has performed contract research for Biogen MA Inc, and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), and Springer Healthcare. WF is a consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc and Roche. All funding is paid to her institution. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is an associate editor at Brain.